Late enhancement cardiac MR imaging techniques, including T1 quantification and extracellular volume fraction, are evolving to improve the diagnosis of ischemic and nonischemic cardiomyopathies.
This review provides a comprehensive guide to current and emerging late enhancement cardiac MR imaging techniques for diagnosing and characterizing cardiomyopathies.
Late enhancement imaging is used to diagnose and characterize a wide range of ischemic and nonischemic cardiomyopathies, and its use has become ubiquitous in the cardiac MR exam. As the use of late enhancement imaging has matured and the span of applications has widened, the demands on image quality have grown. The characterization of subendocardial MI now includes the accurate quantification of scar size, shape, and characterization of borders which have been shown to have prognostic significance. More diverse patterns of late enhancement including patchy, mid-wall, subepicardial, or diffuse enhancement are of interest in diagnosing nonischemic cardiomyopathies. As clinicians are examining late enhancement images for more subtle indication of fibrosis, the demand for lower artifacts has increased. A range of new techniques have emerged to improve the speed and quality of late enhancement imaging including: methods for acquisition during free breathing, and fat water separated imaging for characterizing fibrofatty infiltration and reduction of artifacts related to the presence of fat. Methods for quantification of T1 and extracellular volume fraction are emerging to tackle the issue of discriminating globally diffuse fibrosis from normal healthy tissue which is challenging using conventional late enhancement methods. The aim of this review will be to describe the current state of the art and to provide a guide to various clinical protocols that are commonly used.
Kellman et al. (Fri,) conducted a review in Ischemic and nonischemic cardiomyopathies. Late enhancement cardiac MR imaging was evaluated. Late enhancement cardiac MR imaging techniques, including T1 quantification and extracellular volume fraction, are evolving to improve the diagnosis of ischemic and nonischemic cardiomyopathies.